Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Tessera Therapeutics
Biotech
Regeneron inks $150M pact with gene writer Tessera
The companies will jointly develop and commercialize Tessera's TSRA-196, a near-clinic candidate for alpha-1 antitrypsin deficiency (AATD).
Zoey Becker
Dec 1, 2025 11:12am
ASGCT 2023: New preclinical updates from Tessera, Tune and more
May 23, 2023 10:00am
Biotech's top money raisers: 2022
Apr 11, 2023 9:19am
Tessera makes the case for gene writing tech at JPM
Jan 17, 2023 12:56pm
Execs contemplate gene editing's next 10 years
Oct 3, 2022 3:00am
Former Takeda exec takes reins at Tessa—Chutes & Ladders
Aug 26, 2022 9:30am
